Neon Bloom, Inc. (NBCO)
USD 0.01
(-7.0%)
USD 0.01
(-7.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 770.64 Thousand USD | 94.83% |
| 2022 | 395.53 Thousand USD | -5.93% |
| 2021 | 420.47 Thousand USD | 90.16% |
| 2020 | 221.11 Thousand USD | -67.24% |
| 2019 | 675.02 Thousand USD | -78.03% |
| 2018 | 3.07 Million USD | 15.09% |
| 2017 | 2.66 Million USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2010 | 165.59 Thousand USD | -85.27% |
| 2009 | 1.12 Million USD | 33.02% |
| 2008 | 844.95 Thousand USD | 117.99% |
| 2007 | 387.6 Thousand USD | 11525.73% |
| 2006 | 3334.00 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 925.92 Thousand USD | 21.1% |
| 2024 Q1 | 764.61 Thousand USD | -0.78% |
| 2023 Q2 | 380.64 Thousand USD | -3.77% |
| 2023 Q1 | 395.53 Thousand USD | 0.0% |
| 2023 Q4 | 770.64 Thousand USD | 108.49% |
| 2023 FY | 770.64 Thousand USD | 94.83% |
| 2023 Q3 | 369.62 Thousand USD | -2.9% |
| 2022 Q1 | 501.22 Thousand USD | 19.21% |
| 2022 Q4 | 395.53 Thousand USD | -0.02% |
| 2022 FY | 395.53 Thousand USD | -5.93% |
| 2022 Q3 | 395.6 Thousand USD | 0.0% |
| 2021 FY | 420.47 Thousand USD | 90.16% |
| 2021 Q1 | 364.89 Thousand USD | 0.0% |
| 2021 Q3 | 416.83 Thousand USD | -11.43% |
| 2021 Q4 | 420.47 Thousand USD | 0.87% |
| 2021 Q2 | 470.64 Thousand USD | 28.98% |
| 2020 Q4 | - USD | 0.0% |
| 2020 FY | 221.11 Thousand USD | -67.24% |
| 2019 FY | 675.02 Thousand USD | -78.03% |
| 2018 FY | 3.07 Million USD | 15.09% |
| 2017 FY | 2.66 Million USD | 0.0% |
| 2017 Q4 | 6523.20 USD | 0.0% |
| 2017 Q3 | 6523.20 USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2011 Q1 | 308.45 Thousand USD | 86.27% |
| 2010 Q2 | 1.12 Million USD | 7.28% |
| 2010 Q4 | 165.59 Thousand USD | -81.66% |
| 2010 Q3 | 902.93 Thousand USD | -19.54% |
| 2010 Q1 | 1.04 Million USD | -6.93% |
| 2010 FY | 165.59 Thousand USD | -85.27% |
| 2009 Q2 | 701.61 Thousand USD | -25.43% |
| 2009 Q3 | 605.72 Thousand USD | -13.67% |
| 2009 FY | 1.12 Million USD | 33.02% |
| 2009 Q4 | 1.12 Million USD | 85.55% |
| 2009 Q1 | 940.92 Thousand USD | 11.36% |
| 2008 Q3 | 654.63 Thousand USD | 28.08% |
| 2008 Q4 | 844.95 Thousand USD | 29.07% |
| 2008 Q1 | 471.73 Thousand USD | 21.71% |
| 2008 Q2 | 511.1 Thousand USD | 8.35% |
| 2008 FY | 844.95 Thousand USD | 117.99% |
| 2007 Q3 | 341.14 Thousand USD | 43.43% |
| 2007 Q1 | 215.71 Thousand USD | 0.0% |
| 2007 Q4 | 387.6 Thousand USD | 13.62% |
| 2007 FY | 387.6 Thousand USD | 11525.73% |
| 2007 Q2 | 237.84 Thousand USD | 10.26% |
| 2006 FY | 3334.00 USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -33261.212% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 60.645% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 92.698% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -39.579% |
| Rebus Holdings, Inc. | 5000.00 USD | -15312.88% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.408% |
| Qrons Inc. | 420.00 USD | -183386.667% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 97.242% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -60.365% |
| Skye Bioscience, Inc. | 11.94 Million USD | 93.546% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 98.016% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 89.326% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -909.304% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.281% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 46.185% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -964.94% |
| Mesoblast Limited | 667.9 Million USD | 99.885% |
| Marizyme, Inc. | 22.01 Million USD | 96.499% |
| Genus plc | 1.02 Billion USD | 99.925% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 43.266% |
| Pharming Group N.V. | 462.85 Million USD | 99.834% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 76.739% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -54.426% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -22.91% |
| ContraFect Corporation | 20.67 Million USD | 96.273% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -97.416% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -101.646% |
| IMV Inc. | 31.33 Million USD | 97.541% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 81.412% |
| MultiCell Technologies, Inc. | 126.22 USD | -610456.172% |
| ONE Bio Corp. | 70.08 Million USD | 98.9% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 17.989% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.4% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -78.508% |
| Q BioMed Inc. | 3.51 Million USD | 78.079% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 97.809% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -194.953% |
| Biomind Labs Inc. | 73.81 Thousand USD | -943.964% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.827% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 46.81% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 97.432% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 71.939% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -12.096% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 70.396% |
| GB Sciences, Inc. | 103.44 Thousand USD | -645.001% |
| Alpha Cognition Inc. | 2.45 Million USD | 68.573% |
| HST Global, Inc. | 1526.00 USD | -50400.917% |
| CSL Limited | 38.02 Billion USD | 99.998% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 21.997% |
| Halberd Corporation | 10.13 Thousand USD | -7506.791% |
| Enzolytics Inc. | 361.7 Million USD | 99.787% |
| Agentix Corp. | 261.39 Thousand USD | -194.823% |
| Resverlogix Corp. | 8.11 Million USD | 90.503% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 58.962% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.983% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 98.384% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -20.478% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -3282.837% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 91.389% |
| AVAX Technologies, Inc. | 7.37 Million USD | 89.554% |
| Zenith Capital Corp. | 7410.00 USD | -10300.054% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.977% |
| Ember Therapeutics, Inc. | 184.00 USD | -418728.261% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -139.475% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -194.855% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 16.953% |
| Kadimastem Ltd | 2.3 Million USD | 66.553% |
| Helix BioMedix, Inc. | 3.02 Million USD | 74.525% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 98.538% |
| BioStem Technologies, Inc. | 14.56 Million USD | 94.707% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -1249.781% |
| LadRx Corporation | 2.3 Million USD | 66.608% |
| Cell Source, Inc. | 195.17 Thousand USD | -294.856% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -117.932% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -117.932% |
| NovAccess Global Inc. | 62.24 Thousand USD | -1138.022% |
| Affymax, Inc. | 7.44 Million USD | 89.646% |
| Itoco Inc. | 1.4 Million USD | 44.957% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -705.633% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -627.023% |
| Mobile Lads Corp. | 52.00 USD | -1481907.692% |
| CytoDyn Inc. | 11.13 Million USD | 93.08% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -439.017% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -4210.089% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -99.923% |
| SYBLEU INC | 330.46 Thousand USD | -133.198% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -88.227% |
| International Stem Cell Corporation | 5.39 Million USD | 85.702% |
| Bioxytran, Inc. | 137.63 Thousand USD | -459.906% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 94.863% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 95.352% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -875.499% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 10.875% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 89.748% |
| Neutra Corp. | 2851.00 USD | -26930.656% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 97.622% |
| PureTech Health plc | 693.97 Million USD | 99.889% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 90.452% |
| IXICO plc | 15.84 Million USD | 95.136% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 90.695% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.254% |
| CSL Limited | 38.02 Billion USD | 99.998% |
| Cellectis S.A. | 333.99 Million USD | 99.769% |